Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration

Author's Avatar
Aug 29, 2018
Article's Main Image
  • OPTIC Phase 1 clinical trial initiation expected in 4Q18
  • Patients to receive a single administration of ADVM-022 delivered intravitreally
  • 6 top U.S. retinal centers participating in the new OPTIC trial